Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
Heart failure is a clinical syndrome responsible for at least one-third of hospitalisations amongst cardiac patients, with escalating mortality and healthcare costs on both public and private health care. Both prevalence and incidence of heart failure increase steeply with advancing age, making it a...
Guardado en:
Autores principales: | M. O.E. Irhuma, M. Vally |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
AOSIS
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/801839061dbb4212a01f2e4dfd12d184 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
por: Cuthbert JJ, et al.
Publicado: (2020) -
Reply to Siniorakis et al., “COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure”
por: David S. Fedson, et al.
Publicado: (2020) -
Recent and Upcoming Drug Therapies for Pediatric Heart Failure
por: Karla L. Loss, et al.
Publicado: (2021) -
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
por: Domingo Pascual-Figal, et al.
Publicado: (2021) -
Effect of Angiotensin–Neprilysin Versus Renin–Angiotensin System Inhibition on Renal Outcomes: A Systematic Review and Meta-Analysis
por: Ying Xu, et al.
Publicado: (2021)